3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Uterine Cervical Neoplasms
7
Papillomavirus Infections
6
Neoplasms
5
Breast Neoplasms
4
Uterine Cervical Dysplasia
3
Melanoma
3
Lung Neoplasms
3
Herpes Zoster
3
Condylomata Acuminata
3
Vulvar Neoplasms
2
Prostatic Neoplasms
2
Influenza, Human
2
Anus Neoplasms
2
Wilms Tumor
1
Whooping Cough
1
Waldenstrom Macroglobulinemia
1
Vaginal Neoplasms
1
Tetanus
1
Squamous Cell Carcinoma of Head and Neck
1
Spondylitis, Ankylosing
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rheumatic Diseases
1
Recurrence
1
Psoriasis
1
Persistent Infection
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms, Glandular and Epithelial
1
Nasopharyngeal Neoplasms
1
Interventions
Cyclophosphamide
32
Tacrolimus
29
fludarabine
27
Mycophenolic Acid
23
fludarabine phosphate
22
Busulfan
19
Whole-Body Irradiation
18
Melphalan
16
Methotrexate
15
Antilymphocyte Serum
14
Rituximab
12
Bortezomib
11
Stem Cell Transplantation
10
Cyclosporine
10
thymoglobulin
9
Sirolimus
9
Granulocyte Colony-Stimulating Factor
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Interviews as Topic
7
Filgrastim
7
Dexamethasone
7
Clofarabine
7
Blood Specimen Collection
6
Alemtuzumab
6
merphos
5
Voriconazole
5
Standard of Care
5
Nivolumab
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Neoplasms
×
Vaccines
×
Clear all
NCT01254630
2019-09-30
V212-011
Merck Sharp & Dohme LLC
Phase 3
Completed
5,305 enrolled
20 charts